双歧杆菌联合利那洛肽治疗对老年便秘型肠易激综合征患者疗效、肠道菌群、胃肠道功能、免疫功能的影响  

Effect of bifidobacterium combined with linaclotide on curative effect,intestinal flora,gastrointestinal function,and immune function in elderly patients with constipation irritable bowel syndrome

作　　者：和琳 赵菊珍[2] 马龙飞[2] He Lin;Zhao Ju-zhen;Ma Long-fei(Department of Internal Medicine,Jiaozuo Third People's Hospital,Jiaozuo 454000,Henan,China;Department of Endocrinology,Jiaozuo People's Hospital,Jiaozuo 454000,Henan,China)

机构地区：[1]焦作市第三人民医院内科,河南焦作454000 [2]焦作市人民医院内分泌科,河南焦作454000

出　　处：《四川生理科学杂志》2023年第10期1841-1844,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:探讨双歧杆菌联合利那洛肽胶囊治疗老年便秘型肠易激综合征(Constipation irritable bowel syndrome,C-IBS)患者的临床疗效。方法:选取我院2020年5月至2022年3月收治的128例老年C-IBS患者,根据药物方案不同,分为利那洛肽组和联合用药组,各64例。利那洛肽组采用利那洛肽胶囊治疗,联合用药组采用双歧杆菌四联活菌片和利那洛肽胶囊联合治疗。治疗4 w后,比较两组临床疗效,采用胃肠道症状评定量表(Gastrointestinal symptom rating scale,GSRS)评估患者的胃肠道症状,采用厌氧培养方法统计乳酸杆菌、双歧杆菌、拟杆菌数量,需氧培养方法统计肠杆菌数量,采用放射免疫法测定血清血管活性肠肽(Vasoactive intestinal peptide,VIP)、生长抑素、一氧化氮、胃动素水平,采用酶联免疫吸附法测定血清白细胞介素(Interleukin,IL)-4、IL-10、IL-12、干扰素-γ水平。结果:治疗4 w后,联合用药组临床总有效率高于利那洛肽组(P<0.05);联合用药组GSRS评分、肠杆菌、拟杆菌数量、血清VIP、生长抑素、一氧化氮、IL-12、干扰素-γ水平低于利那洛肽组(P<0.05),肠道乳酸杆菌、双歧杆菌数量、血清胃动素、IL-4、IL-10水平高于利那洛肽组(P<0.05)。结论:双歧杆菌联合利那洛肽胶囊治疗老年C-IBS患者可显著提高临床疗效,改善临床症状,纠正肠道菌群失衡,提高胃肠道功能和Th1/Th2免疫功能。Objective:To investigate the clinical efficacy of bifidobacterium combined with linaclotide capsules in the treatment of elderly patients with constipation irritable bowel syndrome(C-IBS).Methods:One hundred and twenty-eight elderly patients with C-IBS admitted to our hospital from May 2020 to March 2022 were collected.According to different drug regimens,they were divided into the linaclotide group and the combined drug group,with 64 patients in each group.The linaclotide group was treated with linaclotide capsules,and the combined drug group was treated with bifidobacterium tetrad live tablets and linaclotide capsules.After 4 weeks of treatment,the clinical efficacy was compared between the two groups,a gastrointestinal symptom rating scale(GSRS)was used to evaluate the gastrointestinal symptoms,and an anaerobic culture method was used to count the number of lactobacillus,bifidobacterium,and bacteroides.The aerobic culture method was used to count the number of enterobacteria,radioimmunoassay was used to measure the serum levels of vasoactive intestinal peptide(VIP),somatostatin,nitric oxide,and motilin,the enzyme-linked immunosorbent assay was used to measure serum levels of interleukin(IL)-4,IL-10,IL-12,and interferon-γ.Results:After 4 weeks of treatment,the total clinical effective rate of the combined drug group was higher than that of the linaclotide group(P<0.05),GSRS score,enterobacter,Bacteroides,serum levels of VIP,somatostatin,nitric oxide,IL-12,interferon-γin the combined drug group were lower than those in the linaclotide group,and the lactobacillus and bifidobacterium,serum levels of motilin,IL-4 and IL-10 were higher than those in the linaclotide group(P<0.05).Conclusion:Bifidobacterium combined with linaclotide capsule can significantly improve clinical efficacy,improve clinical symptoms,correct intestinal flora imbalance,and improve gastrointestinal function and Th1/Th2 immune function in elderly patients with C-IBS.

关 键 词：利那洛肽 双歧杆菌 便秘型肠易激综合征 肠道菌群 

分 类 号：R574.4[医药卫生—消化系统]